Genmab Terminates Early-Stage GEN1057 Cancer Trial: What Investors Should Watch Next

Genmab (Otc) (GMAB) announced an update on their ongoing clinical study.

The trial called “A First-In-Human, Open-Label, Dose Escalation Trial” tests Genmab’s antibody GEN1057 in people with advanced or metastatic solid tumors. It aims to check basic safety, dose range, and early signs of tumor control, making it an important but early signal for the company’s next wave of oncology drugs.

The treatment is GEN1057, an antibody given as an intravenous infusion, plus routine premedication to manage side effects. The goal is to see how patients tolerate the drug on its own and whether it slows or shrinks tumors that have few other options.

The design is simple and typical for a Phase 1 cancer study. Patients are assigned in a non-random, stepwise fashion to rising dose levels, everyone knows what they get, and the main focus is treatment safety rather than comparing against another drug or placebo.

The trial started enrolling in late August 2024, marking the first clinical test of GEN1057 in humans. The listing was last updated on May 5, 2026, and the study is now labeled terminated, signaling that no new patients are being treated and the initial plan has been halted.

Terminating an early-stage trial like this can weigh on sentiment toward GMAB, as investors may question the broader pipeline strength and risk profile. At the same time, Genmab has multiple approved products and other programs, so the market impact may be contained versus smaller peers that rely on a single asset.

For investors, this update underlines the volatility of early oncology bets and the importance of portfolio diversification within the sector. The GEN1057 trial status and any emerging safety or activity data could still inform Genmab’s future projects and partner discussions, with full details available on the ClinicalTrials portal.

To learn more about GMAB’s potential, visit the Genmab (Otc) drug pipeline page.